Time to Buy ANGLE plc After Today’s Huge Increase?

 Time to Buy ANGLE plc After Today's Huge Increase?

The stock of ANGLE plc (LON:AGL) is a huge mover today! The stock increased 1.64% or GBX 1 on November 24, hitting GBX 62. About 41,222 shares traded hands. ANGLE plc (LON:AGL) has declined 10.95% since April 25, 2016 and is downtrending. It has underperformed by 16.36% the S&P500.
The move comes after 5 months positive chart setup for the GBX 46.39 million company. It was reported on Nov, 24 by Barchart.com. We have GBX 63.86 PT which if reached, will make LON:AGL worth GBX 1.39M more.

More notable recent ANGLE plc (LON:AGL) news were published by: Marketwired.com which released: “Angle PLC Announces New Publications Utilising Parsortix” on April 29, 2016, also Marketwired.com with their article: “Angle PLC: Barts Research Supports Potential Use of Parsortix” published on November 04, 2016, Marketwired.com published: “ANGLE PLC: Research Published in Clinical Chemistry” on September 30, 2016. More interesting news about ANGLE plc (LON:AGL) were released by: Marketwired.com and their article: “ANGLE plc (“the Company”): Initiation of 200 Patient United States Ovarian …” published on July 27, 2016 as well as News.Sys-Con.com‘s news article titled: “ANGLE plc: Result of GM” with publication date: November 24, 2016.

ANGLE plc is a holding company. The Company’s principal activity is undertaken in relation to the commercialization of its Parsortix cell separation system, with deployment in non-invasive cancer diagnostics. The company has a market cap of 46.39 million GBP. The Firm is a specialist medical diagnostic company, which offers products for cancer diagnostics and fetal health. It currently has negative earnings. The Company’s Parsortix cell separation system uses a microfluidic technology in the form of a one-time use cassette to capture and then harvest circulating tumor cells from blood.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment